MedTrace Logo

Effectiveness of Major Ozone Autohemotherapy in the Treatment of Fibromyalgia Syndrome

NCT05034770 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2022-08-05

No results posted yet for this study

Summary

Patients who were admitted to the Physical Medicine and Rehabilitation (PMR) outpatient clinic of our hospital between January 2017 and December 2020 and were treated with Major ozone autohemotherapy with a diagnosis of Fibromyalgia syndrome will include to the study. Visual anolog scale (VAS), Fibromyalgia Impact Questionnare (FIQ) and Short Form Health Survey-36 (SF-36) scores of the patients before and after treatment were recorded. Statistical analysis of these outcome scores will be made.

Conditions

  • Fibromyalgia Syndrome

Interventions

OTHER

major ozone autohemotherapy

This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.

Sponsors & Collaborators

  • Emine Dundar Ahi, MD

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2022-01-10
Completion
2022-01-11

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034770 on ClinicalTrials.gov